<DOC>
	<DOCNO>NCT02517320</DOCNO>
	<brief_summary>The purpose study evaluate efficacy MT-3995 subject diabetic nephropathy , compare placebo , use urine albumin- to-creatinine ratio ( UACR ) first morning void urine sample indicator .</brief_summary>
	<brief_title>Efficacy Safety MT-3995 Patients With Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Type 2 diabetes mellitus Glycated hemoglobin ( HbA1c ) value ( National Glycohemoglobin Standardization Program : NGSP ) ≤10.5 % estimate glomerular filtration rate ( eGFR ) ≥30 mL/min/1.73 m2 The median UACR first morning void urine sample ≥50 mg/g Cr &lt; 300 mg/g Cr Stable blood pressure ( diastolic blood pressure ( DBP ) &lt; 100 mmHg stable systolic blood pressure ( SBP ) &lt; 160 mmHg ) Type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes . A diagnosis nondiabetic renal disease . A following serum potassium level . eGFR 3059mL/min/1.73m2 ; serum potassium level &lt; 3.5 &gt; 4.7 mmol/L , eGFR ≥60mL/min/1.73m2 : serum potassium level &lt; 3.5 &gt; 5.0 mmol/L symptomatic clinically significant hypotension ( diastolic blood pressure ( DBP ) &lt; 50mmHg systolic blood pressure ( SBP ) &lt; 110mmHg ) QT prolongation torsades de pointes , , history family history QT prolongation torsades de point New York Heart Association ( NYHA ) Class III IV heart failure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetic Nephropathy</keyword>
</DOC>